Tricitrates Oral Solution, USP Rx ONLY

Manufacturer
Chartwell RX, LLC
Effective date
2025-04-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
full-release
Hydrated at
2026-05-31 21:32:19

Label at a glance#

ProductTricitrates
Active ingredientPOTASSIUM CITRATE, SODIUM CITRATE, CITRIC ACID MONOHYDRATE
Label structure9 sections

Dosage and administration

Tricitratesoral solution should be taken diluted in water, followed by additional water, if desired. Palatability is enhanced if chilled before taking. Usual Adult Dose 3 to 6 teaspoonfuls (15 to 30 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician. Usual Pediatric Dose 1 to 3 teaspoonfuls (5 to 15 mL), diluted in water, four times a day, after meals and at bedtime,...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Tricitrates Oral Solution, USP is a stable orange colored and cherry flavored oral systemic alkalizer containing potassium citrate, sodium citrate, and citric acid in a sugar-free, non-alcoholic base.

Tricitrates Oral Solution, USP contains in each teaspoonful (5 mL):

Potassium Citrate Monohydrate, USP 550 mg

Sodium Citrate Dihydrate, USP 500 mg

Citric Acid Monohydrate, USP 334 mg

Each mL contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HCO 3).

Inactive Ingredients:saccharin sodium, sodium benzoate, sorbitol solution, FD&C yellow # 6, wild cherry flavor, and purified water.

ACTIONS

Potassium citrate and sodium citrate are absorbed and metabolized to potassium bicarbonate and sodium bicarbonate, thus acting as systemic alkalizers. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the citrates are excreted in the urine unchanged.

INDICATIONS AND ADVANTAGES

INDICATIONS & USAGE SECTION

Tricitrates oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Severe renal impairment with oliguria or azotemia, untreated Addison's disease, or severe myocardial damage. In certain situations, when patients are on a sodium-restricted diet, the use of potassium citrate may be preferable; or, when patients are on a potassium-restricted diet, the use of sodium citrate may be preferable.

PRECAUTIONS AND WARNINGS

WARNINGS AND PRECAUTIONS SECTION

Should be used with caution by patients with low urinary output or reduced glomerular filtration rates unless under the supervision of a physician. Aluminum-based antacids should be avoided in these patients. Patients should be directed to dilute adequately with water and, preferably, to take each dose after meals, to minimize the possibility of gastrointestinal injury associated with oral ingestion of potassium salt preparations and to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy.

Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Periodic examination and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Tricitrates oral solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis, especially in the presence of hypocalcemia. Potassium intoxication causes listlessness, weakness, mental confusion, and tingling of extremities. 

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Tricitratesoral solution should be taken diluted in water, followed by additional water, if desired. Palatability is enhanced if chilled before taking.

Usual Adult Dose

3 to 6 teaspoonfuls (15 to 30 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose

1 to 3 teaspoonfuls (5 to 15 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician.

Usual Dosage Range

2 to 3 teaspoonfuls (10 to 15 mL), diluted with water, taken four times a day, will usually maintain a urinary pH of 6.5-7.4. 3 to 4 teaspoonfuls (15 to 20 mL), diluted with water, taken four times a day, will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urine pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.

OVERDOSAGE

OVERDOSAGE SECTION

Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions. Overdosage with potassium salts may cause hyperkalemia and alkalosis, especially in the presence of renal disease.

HOW SUPPLIED

HOW SUPPLIED SECTION

Tricitrates Oral Solution, USP (orange colored, cherry flavored) is supplied in the following oral dosage form:

16 fl oz (473 mL) bottles                   NDC 62135-438-47

5 mL Unit-Dose Cup                         NDC 62135-438-05

20 Unit-Dose Cups of 5 mL              NDC 62135-438-24

STORAGE

Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from excessive heat and freezing.

SHAKE WELL BEFORE USING.

Manufactured for:

Chartwell RX, LLC.

Congers, NY 10920

L71160

Rev. 04/2025

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Tricitrates Oral Solution, USP - NDC 62135-438-47 - 473 mL (16 fl oz) Bottle Label

Tricitrates Oral Solution, USP - NDC 62135-438-47 - 473 mL (16 fl oz) Bottle Label
Tricitrates Oral Solution, USP - NDC 62135-438-47 - 473 mL (16 fl oz) Bottle Label

Tricitrates Oral Solution, USP - NDC 62135-438-05 - 5 mL Unit-Dose Cup Label

Tricitrates Oral Solution, USP - NDC 62135-438-47 - 473 mL (16 fl oz) Bottle Label
Tricitrates Oral Solution, USP - NDC 62135-438-47 - 473 mL (16 fl oz) Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309317citric acid 334 MG / potassium citrate 550 MG / sodium citrate 500 MG in 5 mL Oral SolutionPSN6
309317citric acid 66.8 MG/ML / potassium citrate 110 MG/ML / sodium citrate 100 MG/ML Oral SolutionSCD6
309317citric acid 334 MG / potassium citrate 550 MG / sodium citrate 500 MG per 5 ML Oral SolutionSY6
309317Citric Acid 66.8 MG/ML / K+ citrate 110 MG/ML / sodium citrate 100 MG/ML Oral SolutionSY6
309317Citric Acid 66.8 MG/ML / Pot citrate 110 MG/ML / sodium citrate 100 MG/ML Oral SolutionSY6

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
c6f86816-7da6-43ea-8c25-ac9758311cc5Product name120220118
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906Product name720210625
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
252e11b6-1a9a-4283-a242-df2c129c496dProduct name320170717
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
62135-438-05Tricitrates5 mL in 1 CUPSOLUTION56
62135-438-24Tricitrates10 in 1 TRAYSOLUTION106
62135-438-24Tricitrates2 in 1 BOXSOLUTION26
62135-438-47Tricitrates473 mL in 1 BOTTLESOLUTION4736

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
62135-438TRICITRATES SOLUTION [CHARTWELL RX, LLC]6Current NDC, Legacy NDC, 4 package rows20250429_2a80ea6b-6334-4c33-a35e-a5cb2939fbcb.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
62135-438-05ML - Milliliter62135-438f9bcf808-2c1d-4176-929a-69695b52504c12025-05-14
62135-438-24ML - Milliliter62135-43865653493-a074-4656-84b6-7e3db13cda5812025-05-14
62135-438-47ML - Milliliter62135-438129d2930-641c-40df-bb31-1946217e3ea012023-01-09

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
62135-43862135-438-47, 62135-438-05, 62135-438-24

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TricitratesTRICITRATESChartwell RX, LLC2a80ea6b-6334-4c33-a35e-a5cb2939fbcb2025-04-28Warnings, Adverse reactionsExact identifier
ndc (package): 62135-438-05
ndc (package): 62135-438-47
ndc (package): 62135-438-24
ndc (product): 62135-438
ndc11 (package): 62135043824
ndc11 (package): 62135043847
ndc11 (package): 62135043805
spl id: 33d7941b-0652-9528-e063-6394a90a8a55
spl set id: 2a80ea6b-6334-4c33-a35e-a5cb2939fbcb

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.